In September, former hedge fund manager Martin Shkreli generated headlines and outrage when his company, Turing Pharmaceuticals AG, raised the price of a lifesaving drug by 5,000 percent. The cost of Daraprim, a drug sold exclusively by select Walgreens pharmacies, jumped from $13.50 to $750 a tablet.
Mr. Shkreli quickly became the smirking face of corporate greed in America. His explanation that his company had to raise the price of Daraprim to fund more research and development costs was laughable. Daraprim — used by victims of a parasitic disease often contracted by eating undercooked, contaminated meat and to treat malaria — is 62 years old and well established; it is not an experimental drug.
After a well-deserved shellacking in the media, Mr. Shkreli said he would consider cutting the list price of Daraprim to make it more affordable. But, after several months out of the spotlight, Mr. Shkreli reneged.
To blunt the force of the later decision, Mr. Shkreli said his company will offer discounts of 50 percent to hospitals that buy the pills to fight the brain-damaging disease. It also will give Daraprim free to uninsured patients and those with incomes below 500 percent of poverty level.
It would’ve been better if Mr. Shkreli had shown his concern for low- and middle-income patients by rolling back Daraprim’s price to $13.50 a pill. The company’s concessions are welcome, but Mr. Shkreli will have to do far more than that to improve his reputation. He could start by apologizing for jacking up the price just because he thought he could get away with it.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.